Prandin: Withdrawal of the application to change the marketing authorisation

repaglinide

Overview

On 12 October 2006, Novo Nordisk A/S officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a change to the marketing authorisation for NovoNorm/Prandin, to add the use of NovoNorm/Prandin in combination with a thiazolidinedione for the treatment of type 2 diabetes.

  • List item

    Questions and answers on the withdrawal of the application for a change to the marketing authorisation for NovoNorm/Prandin (PDF/42.39 KB)


    First published: 18/10/2006
    Last updated: 18/10/2006
    EMEA/405238/2006

  • Key facts

    Name
    Prandin
    Product number
    EMEA/H/C/000362
    Date of issue of market authorisation valid throughout the European Union (if applicable)
    29/01/2001
    International non-proprietary name (INN) or common name
    • repaglinide
    Active substance
    • repaglinide
    Date of withdrawal
    12/10/2006
    Company making the application
    Novo Nordisk A/S
    Withdrawal type
    Post-authorisation

    All documents

    Related content

    Related information on withdrawals

    This text will be replaced by the description of taxonomy term "Template for related information on withdrawals" from vocabulary "String replacement".

    How useful was this page?

    Add your rating